한미 ‘라본 디’, 비비안트에 이어 에비스타 제쳤다

글 내용 전체보기

다케다-몰레큘러, 다발성 골수종 치료제 공동개발

글 내용 전체보기

면역항암제 병용투여 강력후보 제넥신 하이루킨 기대↑

글 내용 전체보기

Bay Area’s uBiome Secures $83 Million as It Moves into Drug Development, Taps ex-Novartis CEO for Its Board

글 내용 전체보기

CDC: 14 Million Americans Will Have Alzheimer’s by 2060

글 내용 전체보기

Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services

글 내용 전체보기

Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

글 내용 전체보기

Rhode Island Looks to Beef up Its Life Sciences Jobs

글 내용 전체보기

Should Pharmaceutical Companies Have to Pay for Medicare? The House Can’t Decide

글 내용 전체보기

Going Its Own Way, European Regulators Reject Sarepta’s Exondys 51 for DMD

글 내용 전체보기

September 21 Research Roundup: Zombie Cells, Pancreatic Cancer, Household Cleaners and Obesity, and Genetic Aspects of Laziness

글 내용 전체보기

Acadia Pharma Soars After FDA Investigation Clears Nuplazid of Additional Safety Problems

글 내용 전체보기

Follow These Steps to Secure an Internship

글 내용 전체보기

Release: AbbVie Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families

글 내용 전체보기

Updated: Y-mAbs Therapeutics Looks at a $96 Million IPO

글 내용 전체보기

Could troubled Mylan swing a sale to private equity buyer? One analyst thinks so

글 내용 전체보기

FDA endorses Acadia’s Nuplazid after review of deaths tied to drug

글 내용 전체보기

FDA berates Chinese drugmaker tied to global valsartan recall

글 내용 전체보기

Lilly’s CGRP Emgality and Spark’s Luxturna win CHMP backing, as Sarepta’s Exondys misses

글 내용 전체보기

English court backs NHS in fight with Bayer, Novartis over off-label Avastin use

글 내용 전체보기

FiercePharmaAsia—Keytruda’s China price; Takeda’s Shire asset sale; 2nd ex-GSK scientist guilty plea

글 내용 전체보기